有学者报道普拉克素(prarnipexole)是新型非麦角多巴胺受体激动剂，选择性作用D3受体，可有效改善症状。卡麦角林(cabergoline)是D2受体激动剂，小剂量给药即可改善症状，而且无晨间反跳现象。
基于3505个网页-相关网页
There was no relation between the cumulative dose of cabergoline and the presence of mild, moderate, or severe valve regurgitation.
卡麦角林的累积剂量和轻度、中度、重度瓣膜返流无明显相关。
Objective: Treatment with ergot-derived dopamine agonists, pergolide, and cabergoline has been associated with an increased frequency of valvular heart disease in Parkinson's disease.
目的：使用麦角衍生的多巴胺激动剂，已经证实帕金森病人使用培高利特和卡麦角林可能增加瓣膜心脏病。
应用推荐